Accessibility Menu
Aligos Therapeutics logo

Aligos Therapeutics(NASDAQ) ALGS

Market Cap$28.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-99%
1 Year-41%
1 Month-15%
$4.75
+3.26%
+0.15Today
After hours$4.71-$0.04 (-0.84%)
Aligos Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.752026-08-04
Aligos Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+11.76%USD 4.252026-07-28
1 month-15.03%USD 5.592026-07-02
3 month-25.43%USD 6.372026-05-06
Year to date-49.03%USD 9.322025-12-31
1 year-40.63%USD 8.002025-08-04
3 year-78.53%USD 22.132023-08-04
5 year-98.83%USD 405.752021-08-05
Since inception-98.76%USD 371.252020-10-16

Aligos Therapeutics Financials at a Glance

Market Cap

$28.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.71M

Net Income (TTM)

-$90.32M

EPS (TTM)

-$8.70

P/E Ratio

-0.53

Dividend

$0.00

Beta (Volatility)

1.45 (Average)

Price

$4.75

Volume

81,446.458

Open

$4.68

Previous Close

$4.75

Daily Range

$4.61 - $4.81

52-Week Range

$3.98 - $13.69

Estimated Earnings Date

Aug 6, 2026

ALGS News

A scientist working on a lab sample

Why Aligos Therapeutics Stock Crumbled Today

Eric VolkmanJan 6, 2022

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aligos Therapeutics

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for liver diseases and viral infections. The company employs proprietary small molecule and oligonucleotide platforms to create optimized drug candidates aimed at improving treatment outcomes, particularly in areas like metabolic dysfunction associated steatohepatitis (MASH), chronic hepatitis B (CHB), and COVID-19-related infections.

Products and Services

ALG055009: A small molecule thyroid hormone receptor beta agonist for MASH.

ALG000184: A small molecule Capsid Assembly Modulator for chronic hepatitis B.

ALG125755: An siRNA drug candidate targeting hepatitis B surface antigen production.

ALG097558: A small molecule pan-coronavirus protease inhibitor for COVID-19 treatment.

What Makes Aligos Therapeutics, Inc. Special

Aligos Therapeutics, Inc. distinguishes itself through its diverse pipeline of drug candidates that are potentially first-in-class and best-in-class. The company leverages proprietary technologies to enhance drug efficacy and safety. A seasoned management team supports these efforts by advancing lead candidates through clinical trials and strategically expanding the portfolio through collaborations.

Five Things You Need to Know

Aligos focuses on MASH, CHB, and COVID-19 using innovative drug design and proprietary platforms.

ALG055009 is entering Phase 2 trials and shows promise in improving liver health through THR beta agonism.

ALG000184 demonstrates strong antiviral activity in reducing HBV DNA and RNA in CHB patients.

Collaborations with Merck and other institutions enhance Aligos’s R&D capabilities.

Funding from NIH supports development efforts, emphasizing Aligos's competitive positioning in viral and liver disease therapy.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

82

CEO

Lawrence M. Blatt, PhD, MBA

Website

www.aligos.com

Headquarters

South San Francisco, CA 94080, US

ALGS Financials

Key Financial Metrics (TTM)

Gross Margin

89.03%

Operating Margin

-2033.39%

Net Income Margin

-1919.68%

Return on Equity

-139.47%

Return on Capital

-149.65%

Return on Assets

-139.91%

Earnings Yield

-1.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$28.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.19M

Volume

81.45K

Avg. Volume

173.33K

Financials (TTM)

Gross Profit

$4.19M

Operating Income

-$95.67M

EBITDA

-$88.17M

Operating Cash Flow

-$84.72M

Capital Expenditure

-$463.00K

Free Cash Flow

-$85.19M

Cash & ST Invst.

$55.08M

Total Debt

$4.35M

Aligos Therapeutics Performance Analysis

Aligos Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 13,907,000219.0%
20232023-12-31USD 15,529,00011.7%
20242024-12-31USD 3,945,000-74.6%
20252025-12-31USD 2,186,000-44.6%
Aligos Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30210.3%
Q32025-09-30-23.2%
Q42025-12-31-77.2%
Q12026-03-311574.6%
Aligos Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -34.11N/A
20242024-12-31USD -20.94-38.6%
20252025-12-31USD -2.45-88.3%
Aligos Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3027.5%
Q32025-09-30-98.7%
Q42025-12-3137.2%
Q12026-03-31-15.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.83M

+810.0%

Gross Profit

$2.83M

+810.0%

Gross Margin

100.00%

N/A

Market Cap

$28.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$347.14K

N/A

Employees

82

N/A

Net Income

-$23.04M

-153.5%

EBITDA

-$22.38M

-151.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$55.08M

-60.0%

Total Debt

$4.35M

-44.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$659.00K

-85.0%

Short Term Debt

$3.69M

+5.9%

Return on Assets

-1.40%

N/A

Return on Invested Capital

-2.32%

N/A

Free Cash Flow

-$23.20M

-10.7%

Operating Cash Flow

-$23.13M

-10.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BRNSBarinthus Biotherapeutics plc
$0.56-5.87%
FGENFibroGen, Inc.
$9.07-1.63%
SKYESkye Bioscience, Inc.
$0.58-1.57%
INMBINmune Bio, Inc.
$1.91+3.24%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About ALGS

What is the current price of Aligos Therapeutics?

Aligos Therapeutics is trading at $4.75 per share.

What is the 52-week range for Aligos Therapeutics?

Over the past 52 weeks, Aligos Therapeutics has traded between $3.98 and $13.69.

How much debt does Aligos Therapeutics have?

As of the most recent reporting period, Aligos Therapeutics reported total debt of $4.35M.

How much cash does Aligos Therapeutics have on hand?

Aligos Therapeutics reported $30.15M in cash and cash equivalents in its most recent financial results.

What is Aligos Therapeutics’s dividend yield?

Aligos Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services